TY - JOUR T1 - Use of Hemospray® in post-sclerotherapy bleeding JO - Boletín Médico del Hospital Infantil de México (English Edition) T2 - AU - González Ortiz,Beatriz AU - Tapia Monge,Dora María AU - Reyes Cerecedo,Alicia AU - Hernández Mondragón,Oscar SN - 24443409 M3 - 10.1016/j.bmhime.2017.11.003 DO - 10.1016/j.bmhime.2017.11.003 UR - https://www.elsevier.es/en-revista-boletin-medico-del-hospital-infantil-201-articulo-use-hemospray-in-post-sclerotherapy-bleeding-S2444340917000358 AB - BackgroundHemospray® is a new device for endoscopic hemostasis used for non-variceal gastrointestinal bleeding. It enables hemostasis and platelet activation by increasing the concentration of clotting factors and forming a mechanical barrier on the wall of a bleeding vessel creating a mechanical plug at the site of bleeding. Within the main indications for use are injuries with difficult endoscopic access, massive gastrointestinal bleeding, multiple bleeding sites, modification of the anatomy by previous endoscopic therapy, presence of coagulopathy, difficulty in having direct visualization or when it is impossible to have contact with the bleeding lesion. However, its use in children has not been approved yet by the FDA. There is a case report of an 11-month-old patient successfully treated with Hemospray® for non-variceal gastrointestinal bleeding. Clinical caseWe report the case of a 2-year-old female with acute liver failure and primary biliary cirrhosis with portal hypertension and bleeding after sclerotherapy. We analyzed the case to support new therapies for massive bleeding control in post-sclerotherapy esophageal ulcers. ConclusionsThe application showed to be safe without side effects. Using Hemospray® is an effective alternative in controlling gastrointestinal bleeding. ER -